Journal Article10.1097/HCO.0000000000000375
Management of heart failure in the elderly.
Faisal Alghamdi,Michael Chan +1 more
18
TL;DR: In general, the elderly patient with heart failure should be treated according to current heart failure guidelines; however, untailored heart failure management may cause untoward effects in this age group and may worsen clinical outcome.
read more
Abstract: Purpose of reviewHeart failure is a major chronic illness with no definitive cure. With improving healthcare and with an aging population in many countries, heart failure has become a common disease of the elderly. Pharmacological management of heart failure in the elderly remains a challenge. The s
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement.
Simon Stewart,Barbara Riegel,Cynthia M. Boyd,Yasmin Ahamed,David R. Thompson,Louise M Burrell,Melinda Carrington,Andrew J.S. Coats,Bradi B. Granger,Julie A. Hides,William S. Weintraub,Debra K. Moser,Victoria Vaughan Dickson,Cressida J. McDermott,Ashley K. Keates,Michael W. Rich +15 more
TL;DR: A clinical framework, comprising five key steps, is proposed for improving typically poor health outcomes in those affected by multimorbidity in HF.
52
Myocardial Cell Signaling During the Transition to Heart Failure: Cellular Signaling and Therapeutic Approaches.
Matthew R. Zeglinski,Adel Rezaei Moghadam,Sudharsana R. Ande,Kimia Sheikholeslami,Kimia Sheikholeslami,Pooneh Mokarram,Zahra Sepehri,Zahra Sepehri,Haleh Rokni,Nima Khadem Mohtaram,Nima Khadem Mohtaram,Mansour Poorebrahim,Anahita Masoom,Mehnosh Toback,Niketa Sareen,Sekaran Saravanan,Sekaran Saravanan,Davinder S. Jassal,Mohammad Hashemi,Hassan Marzban,Dedmer Schaafsma,Pawan K. Singal,Jeffrey T. Wigle,Michael P. Czubryt,Mohsen Akbari,Ian M.C. Dixon,Saeid Ghavami,Saeid Ghavami,Joseph W. Gordon,Sanjiv Dhingra +29 more
TL;DR: This review summarizes the signaling pathways implicated in the transition to HF following cardiac injury and provides an update on cell death signaling and discusses recent advances in cardiac fibrosis as an independent event leading to HF.
18
Aging and atrial fibrillation: A vicious circle.
Pan Gao,Xinyi Gao,Bingxin Xie,Gary Tse,Tong Liu +4 more
TL;DR: The recent advances in studies investigating the relationship between aging and AF and the possible underlying mechanisms are discussed.
11
•Journal Article
Heart failure in the elderly.
TL;DR: In intractable heart failure other agents ie inotropic agents and vasodilators may be considered and routine maintenance on diuretic and digoxin should not be encouraged.
9
The Prescription of Vitamin K Antagonists in a Very Old Population: A Cross-Sectional Study of 8696 Ambulatory Subjects Aged Over 85 Years
Patrick Manckoundia,Clémentine Rosay,Didier Menu,Valentine Nuss,Anca-Maria Mihai,Jérémie Vovelle,Gilles Nuemi,Philippe d’Athis,Alain Putot,Jérémy Barben +9 more
TL;DR: The VKA and noVKA groups were compared in terms of demographic conditions, registered chronic diseases (RCD), number of drugs per prescription and cardiovascular medications, and fluindione was the most commonly prescribed VKA.
4
References
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer,Gerasimos Filippatos,John J.V. McMurray,Victor Aboyans,Stephan Achenbach,Stefan Agewall,Nawwar Al-Attar,John Atherton,Johann Bauersachs,A. John Camm,Scipione Carerj,Claudio Ceconi,Antonio Coca,Perry M. Elliott,Çetin Erol,Justin A. Ezekowitz,Covadonga Fernández-Golfín,Donna Fitzsimons,Marco Guazzi,Maxime Guenoun,Gerd Hasenfuss,Gerhard Hindricks,Arno W. Hoes,Bernard Iung,Tiny Jaarsma,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Stavros Konstantinides,Mitja Lainscak,Patrizio Lancellotti,Gregory Y.H. Lip,Francesco Maisano,Christian Mueller,Mark C. Petrie,Massimo F Piepoli,Silvia G. Priori,Adam Torbicki,Hiroyuki Tsutsui,Dirk J. van Veldhuisen,Stephan Windecker,Clyde W. Yancy,José Luis Zamorano +62 more
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
18.6K
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
12.4K
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Bertram Pitt,Faiez Zannad,Willem J. Remme,Robert J. Cody,Alain Castaigne,Alfonso Perez,Jolie Palensky,Janet Wittes +7 more
TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
8.6K
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer +20 more
TL;DR: ACCF/AHAIAI: angiotensin-converting enzyme inhibitor as discussed by the authors, angio-catabolizing enzyme inhibitor inhibitor inhibitor (ACS inhibitor) is a drug that is used to prevent atrial fibrillation.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Martin Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile,Abstr Act +11 more
TL;DR: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.